Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer | Zendy

John K. Chan | Zendy; Mark F. Brady | Zendy; Richard T. Penson | Zendy; Helen Q. Huang | Zendy; Michael J. Birrer | Zendy; Joan L. Walker | Zendy; Paul DiSilvestro | Zendy; Stephen C. Rubin | Zendy; Lainie P. Martin | Zendy; Susan A. Davidson | Zendy; Warner K. Huh | Zendy; David M. O’Malley | Zendy; Matthew Boente | Zendy; Helen Michael | Zendy; Bradley J. Monk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Author(s) -

John K. Chan,

Mark F. Brady,

Richard T. Penson,

Helen Q. Huang,

Michael J. Birrer,

Joan L. Walker,

Paul DiSilvestro,

Stephen C. Rubin,

Lainie P. Martin,

Susan A. Davidson,

Warner K. Huh,

David M. O’Malley,

Matthew Boente,

Helen Michael,

Bradley J. Monk

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1505067

Subject(s) - carboplatin , paclitaxel , medicine , bevacizumab , ovarian cancer , oncology , chemotherapy , cancer , cisplatin

A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ovarian cancer. We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients receiving and those not receiving bevacizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research